Besides prostate cancer, MSH2 is often overexpressed in melanoma, gastric cancer, and oral squamous cell carcinoma, where it correlates with increased tumour aggressiveness and poor patient prognosis [47,48,49]. This evidence concerns the gene MSH2 and Familial prostate cancer.